Hepatitis C: State of Medicaid Access

Hepatitis C: State of Medicaid Access is the culmination of work by the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) to definitively assess the state of access to DAAs for Medicaid enrollees across America. Through a national report Read more

By HepCAP, ago

AASLD IDSA New Guidance

What’s New, Updates, and Changes to the Guidance This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance. In addition to updates to all the sections, the following new Read more

By HepCAP, ago

New Hep C Drugs

HCVAdvocate.org posted news about another cheaper Hep C drug. Hopefully the market will continue to compete the prices down! Learn more about the FDA drug pipline at http://hcvadvocate.org/treatment/drug-pipeline/#FDA Mavyret

By HepCAP, ago